article thumbnail

$2 billion mRNA-based oncology therapy market anticipated by 2029

European Pharmaceutical Review

The global mRNA-based oncology therapy market is expected to reach $2 billion by 2029, according to GlobalData. percent share by 2029, the research has shown. percent of the total mRNA therapy market by 2029. BioNTech is anticipated to lead the market with a predicted $885 million in sales, and a 44.6

Marketing 110
article thumbnail

Enhancing competitiveness of European life sciences

European Pharmaceutical Review

Conclusions from the meeting of the special European Council (17-18 April 2024) have recognised a need for new European competitiveness deal “anchored in a fully integrated Single Market”. The post Enhancing competitiveness of European life sciences appeared first on European Pharmaceutical Review.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Securing Europe’s competitiveness in life sciences

European Pharmaceutical Review

Nathalie Moll, Director General, the European Federation of Pharmaceutical Industries and Associations (EFPIA), has commended inclusion of a “dedicated life sciences strategy” in the Political Guidelines for the Next European Commission 2024-2029. As such, she noted that the initial priority will be “prosperity and competitiveness.”

article thumbnail

Oncology biosimilar case studies: rituximab biosimilars

Pharmaceutical Technology

However, in the second year of biosimilar competition, Rituxan sales started to significantly erode. GlobalData forecasts Rituxan sales to plummet to just over $300m by 2029, while biosimilars will collectively surpass $1bn in sales in the same year, becoming responsible for nearly 80% of the total market share for rituximab products.

Sales 59
article thumbnail

Biopharma sees strong Q2 2023 market cap growth

European Pharmaceutical Review

billion sales globally by 2029, this could offset Keytruda’s decline sales expected after its loss of exclusivity in 2028, GlobalData highlighted. This is mainly due to the reported decline in sales of Humira, a consequence of biosimilar competition. With the company’s monoclonal antibody drug candidate PRA023 predicted to reach $2.1

article thumbnail

EHA 2023: Kura Oncology’s menin inhibitor ziftomenib shows impressive Phase I results

Pharmaceutical Technology

According to GlobalData’s analyst consensus forecast, global sales for ziftomenib will reach $255m by 2029. Kura faces competition in the menin inhibitor market as the therapy is being developed to treat various indications. GlobalData forecasts total sales from this drug class to exceed $1bn by 2029.

article thumbnail

Merck defends blockbuster Januvia franchise from patent challenge

pharmaphorum

Merck & Co has been fighting to defend its blockbuster type 2 diabetes therapy Januvia from generic competition for years, and a new judgment looks set to protect its third biggest-selling drug for another few years. 8,414,921), which covers the co-formulation of sitagliptin and metformin and is due to expire in 2029.